Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mike mulhearn who wrote (373)	2/22/1997 6:57:00 PM
From: Damon Pham	of 849

First Call report from Dow Jones has it as a buy. ****** Develops and markets Close 6 13/16 Consensus Rec. BUY serum, cell and urine 52-Week High 18 4 Analysts 1.5 based nuclear matrix 52-Week Low 6 1/4 1Q EPS Est (0.04) prottein (NMP) drugs and Dividend Yield None 3 Analysts therapy kits. NMP helps Industry Avg 1.13% 4Q Oper EPS (0.08) detect and monitor presence 1997 EPS Est (0.16) of bladder, breast, colorectal, 6 Analysts cervical and prostate Beta vs DJEI 1.10 1996 Oper EPS (0.32) cancers. On 7/96 its 5-Yr EPS Growth 35.0% bladder cancer test kit 4Q Rev $0.77M +31.7% Industry Avg 17.6% got FDA marketing TTM $2.41M +94.4% P/E Ratio ... approval. 4Q Ern ($1.21M) ... Industry Avg 24.44 TTM ($5.16M) ... Projected P/E None HQ Newton, MA 1-Yr Tot Rtrn (30.12%) IR Phone 617-661-6660 Industry Avg 18.41% Updated 2/20 Sources: First Call, Market Guide

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next